首页 > 过刊浏览>2025年第35卷第5期 >53-59. DOI:10.3969/j.issn.1005-8982.2025.05.009
PDF HTML阅读 XML下载 导出引用 引用提醒
重度哮喘的生物标志物研究进展
作者:
作者单位:

1.山西医科大学 医学科学院， 山西 太原 030001;2.山西医科大学第一医院 呼吸与危重症医学科， 山西 太原 030001

通讯作者:

孔晓梅，E-mail: kongxm@sxmu.edu.cn；Tel: 18835157355

中图分类号:

R562.25

基金项目:

国家自然科学基金（No: 82370024）


Advances in biomarker research for severe asthma
Author:
Affiliation:

1.Academy of Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi 030001, China;2.Department of Respiratory Critical Care Medicine, Shanxi Medical University Affiliated First Hospital, Taiyuan, Shanxi 030001, China

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [47]
    • |
  • 相似文献 [20]
    • | | |
  • 文章评论
    摘要:

    重度哮喘是复杂异质性慢性炎症疾病。近年来，伴随着对重度哮喘发病机制认识的不断深入，其生物标志物的研究取得了显著性进展，其诊断和治疗策略也得到了显著改善。每一种生物标志物都以其独特的方式为重度哮喘的精准医疗提供重要信息。结合国内外最新的研究进展，该文综述了现有及未来可能改善重度哮喘诊疗的新兴组学生物标志物，这些标志物能快速揭示疾病的病理生理过程，进而为精准诊断和个体化治疗提供可靠依据。

    Abstract:

    Severe asthma, characterized as a complex and heterogeneous chronic inflammatory disease, has witnessed significant advancements in biomarker research alongside a deepening understanding of its pathogenesis in recent years. These advancements have markedly improved diagnostic and therapeutic strategies for this condition. Each biomarker contributes uniquely to precision medicine in severe asthma by providing critical insights into its molecular underpinnings. This review synthesizes the latest global research progress on existing and emerging omics-based biomarkers that hold promise for refining the management of severe asthma. These biomarkers rapidly elucidate disease-specific pathophysiological pathways, thereby offering robust evidence to guide precision diagnosis and tailored therapeutic approaches. Furthermore, we highlight future directions in biomarker discovery, emphasizing their potential to overcome current limitations in phenotyping and therapeutic resistance.

    参考文献
    [1] WANG E, WECHSLER M E, TRAN T N, et al. Characterization of severe asthma worldwide: data from the international severe asthma registry[J]. Chest, 2020, 157(4): 790-804.
    [2] 中国医药教育协会慢性气道疾病专业委员会, 中国哮喘联盟. 重度哮喘诊断与处理中国专家共识(2024)[J]. 中华医学杂志, 2024, 104(20): 1759-1789.
    [3] ZHANG Q L, FU X H, WANG C Z, et al. Severe eosinophilic asthma in Chinese C-BIOPRED asthma cohort[J]. Clin Transl Med, 2022, 12(2): e710.
    [4] KOREVAAR D A, WESTERHOF G A, WANG J F, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis[J]. Lancet Respir Med, 2015, 3(4): 290-300.
    [5] PETSKY H L, LI A, CHANG A B. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults[J]. Cochrane Database Syst Rev, 2017, 8(8): CD005603.
    [6] CHOI B S. Eosinophils and childhood asthma[J]. Clin Exp Pediatr, 2021, 64(2): 60-67.
    [7] ZEIGER R S, SCHATZ M, LI Q, et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma[J]. The Journal of Allergy and Clinical Immunology: In Practice, 2014, 2(6): 741-750. e4.
    [8] KATZ L E, GLEICH G J, HARTLEY B F, et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma[J]. Ann Am Thorac Soc, 2014, 11(4): 531-536.
    [9] BUSSE W W, WENZEL S E, CASALE T B, et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis[J]. Lancet Respir Med, 2021, 9(10): 1165-1173.
    [10] 李东丽, 陈斐斐, 孟扬琴. FeNO、EOS与喘息性支气管炎患儿肺功能的相关性及对哮喘的预测价值[J]. 中国现代医学杂志, 2023, 33(23): 22-27.
    [11] PAVORD I D, DENIZ Y, CORREN J, et al. Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma[J]. The Journal of Allergy and Clinical Immunology: In Practice, 2023, 11(4): 1213-1220. e2.
    [12] PALOMARES ó, SáNCHEZ-RAMóN S, DáVILA I, et al. dIvergEnt: how IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies[J]. Int J Mol Sci, 2017, 18(6): 1328.
    [13] YUAN Y L, ZHANG X, LIU L, et al. Total IgE variability is associated with future asthma exacerbations: a 1-year prospective cohort study[J]. J Allergy Clin Immunol Pract, 2021, 9(7): 2812-2824.
    [14] AZIZ D A, BAJWA R A, OMAR M, et al. Immunoglobulin Ige levels and clinical dynamics of asthma in children and adolescents[J]. J Ayub Med Coll Abbottabad, 2023, 35(Suppl 1)(4): S752-S756.
    [15] IZUHARA K, ARIMA K, OHTA S, et al. Periostin in allergic inflammation[J]. Allergol Int, 2014, 63(2): 143-151.
    [16] TAKAHASHI K, MEGURO K, KAWASHIMA H, et al. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics[J]. J Asthma, 2019, 56(3): 236-243.
    [17] HANANIA N A, NOONAN M, CORREN J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies[J]. Thorax, 2015, 70(8): 748-756.
    [18] KOLACZKOWSKA E, KUBES P. Neutrophil recruitment and function in health and inflammation[J]. Nat Rev Immunol, 2013, 13(3): 159-175.
    [19] CHANG H S, LEE T H, JUN J A, et al. Neutrophilic inflammation in asthma: mechanisms and therapeutic considerations[J]. Expert Rev Respir Med, 2017, 11(1): 29-40.
    [20] PETERS M C, MCGRATH K W, HAWKINS G A, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts[J]. Lancet Respir Med, 2016, 4(7): 574-584.
    [21] CHANG Y, AL-ALWAN L, RISSE P A, et al. Th17-associated cytokines promote human airway smooth muscle cell proliferation[J]. FASEB J, 2012, 26(12): 5152-5160.
    [22] XIE Y, ABEL P W, CASALE T B, et al. TH17 cells and corticosteroid insensitivity in severe asthma[J]. J Allergy Clin Immunol, 2022, 149(2): 467-479.
    [23] BRITT R D Jr, THOMPSON M A, SASSE S, et al. Th1 cytokines TNF-α and IFN-γ promote corticosteroid resistance in developing human airway smooth muscle[J]. Am J Physiol Lung Cell Mol Physiol, 2019, 316(1): L71-L81.
    [24] MONADI M, FIROUZJAHI A, HOSSEINI A, et al. Serum C-reactive protein in asthma and its ability in predicting asthma control, a case-control study[J]. Caspian J Intern Med, 2016, 7(1): 37-42.
    [25] PETERSEN B S, FREDRICH B, HOEPPNER M P, et al. Opportunities and challenges of whole-genome and -exome sequencing[J]. BMC Genet, 2017, 18(1): 14.
    [26] DONG Z Z, MA Y L, ZHOU H, et al. Integrated genomics analysis highlights important SNPs and genes implicated in moderate-to-severe asthma based on GWAS and eQTL datasets[J]. BMC Pulm Med, 2020, 20(1): 270.
    [27] VALETTE K, LI Z L, BON-BARET V, et al. Prioritization of candidate causal genes for asthma in susceptibility loci derived from UK biobank[J]. Commun Biol, 2021, 4(1): 700.
    [28] PIVIDORI M, SCHOETTLER N, NICOLAE D L, et al. Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies[J]. Lancet Respir Med, 2019, 7(6): 509-522.
    [29] FORNO E, WANG T, QI CC, et al. DNA methylation in nasal epithelium, atopy, and atopic asthma in children: a genome-wide study[J]. Lancet Respir Med, 2019, 7(4): 336-346.
    [30] DESSIE E Y, DING L L, MERSHA T B. Integrative analysis identifies gene signatures mediating the effect of DNA methylation on asthma severity and lung function[J]. Clin Epigenetics, 2024, 16(1): 15.
    [31] CARDENAS A, SORDILLO J E, RIFAS-SHIMAN S L, et al. The nasal methylome as a biomarker of asthma and airway inflammation in children[J]. Nat Commun, 2019, 10(1): 3095.
    [32] SHEIKHPOUR M, MALEKI M, EBRAHIMI VARGOORANI M, et al. A review of epigenetic changes in asthma: methylation and acetylation[J]. Clin Epigenetics, 2021, 13(1): 65.
    [33] KIERBIED?-GUZIK N, SOZA?SKA B. miRNAs as modern biomarkers in asthma therapy[J]. Int J Mol Sci, 2023, 24(14): 11499.
    [34] GIL-MARTíNEZ M, LORENTE-SOROLLA C, NAHARRO S, et al. Advances and highlights of miRNAs in asthma: biomarkers for diagnosis and treatment[J]. Int J Mol Sci, 2023, 24(2): 1628.
    [35] WEIDNER J, BARTEL S, KILI? A, et al. Spotlight on microRNAs in allergy and asthma[J]. Allergy, 2021, 76(6): 1661-1678.
    [36] CA?AS J A, VALVERDE-MONGE M, RODRIGO-MU?OZ J M, et al. Serum microRNAs as tool to predict early response to benralizumab in severe eosinophilic asthma[J]. J Pers Med, 2021, 11(2): 76.
    [37] WANG C, JIANG S Y, ZHANG S Y, et al. Research progress of metabolomics in asthma[J]. Metabolites, 2021, 11(9): 567.
    [38] MIYATA J, FUKUNAGA K, IWAMOTO R, et al. Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma[J]. J Allergy Clin Immunol, 2013, 131(2): 353-360.e2.
    [39] JIANG T C, DAI L L, LI P F, et al. Lipid metabolism and identification of biomarkers in asthma by lipidomic analysis[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2021, 1866(2): 158853.
    [40] SAVITO L, SCARLATA S, BIKOV A, et al. Exhaled volatile organic compounds for diagnosis and monitoring of asthma[J]. World J Clin Cases, 2023, 11(21): 4996-5013.
    [41] SHARMA A, LAXMAN B, NAURECKAS E T, et al. Associations between fungal and bacterial microbiota of airways and asthma endotypes[J]. J Allergy Clin Immunol, 2019, 144(5): 1214-1227.e7.
    [42] TAYLOR S L, LEONG L E X, CHOO J M, et al. Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology[J]. J Allergy Clin Immunol, 2018, 141(1): 94-103.e15.
    [43] ZHOU Y J, JACKSON D, BACHARIER L B, et al. The upper-airway microbiota and loss of asthma control among asthmatic children[J]. Nat Commun, 2019, 10(1): 5714.
    [44] CHUNG K F. Airway microbial dysbiosis in asthmatic patients: a target for prevention and treatment?[J]. J Allergy Clin Immunol, 2017, 139(4): 1071-1081.
    [45] GOLEVA E, JACKSON L P, HARRIS J K, et al. The effects of airway microbiome on corticosteroid responsiveness in asthma[J]. Am J Respir Crit Care Med, 2013, 188(10): 1193-1201.
    [46] KOCH L. Biomarker benchmarking[J]. Nat Rev Genet, 2022, 23(12): 714.
    [47] SHUMNALIEVA R, ERMENCHEVA P, KOTOV G, et al. New biomarkers for systemic necrotizing vasculitides[J]. J Clin Med, 2024, 13(8): 2264.
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

刘辉,孔晓梅.重度哮喘的生物标志物研究进展[J].中国现代医学杂志,2025,35(5):53-59

复制
分享
文章指标
  • 点击次数:30
  • 下载次数: 8
  • HTML阅读次数: 7
  • 引用次数: 0
历史
  • 收稿日期:2024-08-23
  • 在线发布日期: 2025-03-19
文章二维码

中国现代医学杂志 ® 2025 版权所有 技术支持：北京勤云科技发展有限公司